Core Viewpoint - The company has entered into a collaboration agreement with Zhejiang Zhongshen Innovative Pharmaceutical Technology Co., Ltd. for the development of the BIOS-0629 project, which includes responsibilities for research, clinical trials, and market expansion [1] Group 1: Collaboration Details - The company will handle the research and development, clinical trials, and registration of the product [1] - Zhejiang Zhongshen will be responsible for the research transformation, production, sales, and market expansion in the Greater China region [1] - Upon signing the contract, Zhejiang Zhongshen will pay a milestone fee of 300 million yuan based on research progress [1] Group 2: Financial Incentives - The company will receive a 10% commission on sales revenue once the product is launched in the Greater China market [1]
百诚医药：就BIOS-0629项目签署技术开发合作协议